Atlas Trials

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

Clinical trial NCT07282574 · RECRUITING

Trial details

NCT number
NCT07282574
Sponsor
Hoffmann-La Roche
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Progressive Multiple Sclerosis
Start date
2026-03-10
Primary completion
2028-05-30
Enrollment
360

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.